
A UK-first innovation programme will bring together private healthcare providers and the NHS, to test new ways to prevent, detect and treat heart disease, diabetes and obesity, so that new proven technologies can rapidly reach NHS patients.
New technologies that could help prevent heart attacks and strokes will be tested in independent hospitals and clinics in Harley Street Health District, as part of a first-of-its-kind innovation programme designed to get the most promising ideas to NHS patients across London more quickly.
The Frontier Innovation for Cardiometabolic Disease Programme, backed by £10 million from UK Research and Innovation’s Local Innovation Partnerships Fund, supported by the Mayor of London, brings together partners across London to accelerate the development, validation and adoption of innovations for heart disease, diabetes and obesity.
The £5 million scale-up and adoption arm of the programme, is led by UCLPartners in collaboration with Harley Street Health District, Imperial College Health Partners and Health Innovation Network South London. The programme will enable technology companies to rapidly gather real-world evidence of how well their products work, bringing proven technologies into NHS services, and improving outcomes for people across London.
This is the first time a national public health programme has drawn on the scale and patient reach of London’s independent healthcare sector in this way.
Cardiovascular disease causes one in four deaths in London, around 13,000 a year. Around 70% of it is preventable, yet more than 500,000 Londoners are living with high blood pressure without knowing it.
In the UK, many promising health technologies never reach patients. They stall because companies struggle to gather the evidence the NHS and other healthcare providers need to adopt them. This programme gives those companies a faster route to that evidence.
The programme will focus on a range of technologies across cardiometabolic disease prevention, from identifying people at risk earlier to interventions that help reduce risk, support healthier lifestyles and manage conditions such as high blood pressure and high cholesterol. It will prioritise innovations that can reduce inequalities in heart health and will generate evidence across London’s diverse communities.
The Frontier Innovation for Cardiometabolic Disease Programme aims to leverage up to £300 million in private investment and create up to 1,000 high-value jobs in London. It will engage more than 100 companies, give tailored support to at least 20 and help at least five breakout-stage companies prove their products and scale them through the NHS.
Howard Dawber, Deputy Mayor of London for Business and Growth, said: “London is home to some of the world’s leading hospitals, researchers and innovators, and we’re proud to support this programme to tackle major health challenges including heart disease, diabetes and obesity.
“This collaboration can help pioneer new technologies and treatments, potentially saving lives and improving care for thousands of Londoners, while strengthening our world-leading life sciences sector.”
Professor Kevin Fenton CBE, Regional Director of Public Health, NHS England London, said: “Cardiovascular disease (CVD) causes one in four deaths in London, with the greatest burden falling on our most deprived communities and those experiencing health inequalities. Yet most of this burden is preventable. Hundreds of thousands of Londoners are living with undiagnosed high blood pressure, putting them at unnecessary risk of heart attacks and strokes.
“We know that earlier detection and effective treatment save lives, but we must find new ways to reach people who are too often missed by traditional services. Through our London Million Hearts and Minds CVD Prevention programme, we are bringing together the NHS, local government, communities and industry to accelerate prevention at scale.
“This innovative partnership harnesses the expertise, technology and reach of the independent sector to tackle one of London’s greatest public health challenges. It is a powerful example of how working differently, across traditional boundaries, can help us detect risk earlier, prevent avoidable illness and build a healthier, more equitable London.”
Mark Kildea, Chief Executive of The Howard de Walden Estate, said: “Forty per cent of London’s independent healthcare happens in Harley Street Health District, and we have one of the greatest concentrations of clinical expertise anywhere in the world. Many of the world-leading consultants who practise here also work in the NHS. That gives us a real opportunity to put the independent sector to work on one of London’s most pressing health challenges.
“Through this programme, companies will be able to test their ideas with real patients and build the evidence the NHS needs. Most importantly, it will help good ideas reach patients sooner.”
Dr Chris Laing, Chief Executive Officer, UCLPartners, said: “This partnership is about drawing on London’s world leading assets to bring the most effective innovations to the NHS, so patients across the city can benefit faster from new technologies. By harnessing the agility of private hospitals to test innovations quickly, and the scale of the NHS to adopt what works, we can ensure the best care is available to patients with cardiovascular disease, improving outcomes and experiences for the thousands of people living with this disease”
Dr Dominique Allwood MBE, Chief Executive Officer of Imperial College Health Partners, said: “Cardio-renal-metabolic health is one of our three strategic missions for research and innovation in North West London, reflecting both the scale of the challenge and the opportunity to transform outcomes for patients and communities through innovation. This exciting programme builds on that ambition, providing a vital bridge between promising innovation, real-world evidence and implementation in clinical practice. By combining London’s world-leading research and innovation strengths with the needs of our diverse populations, we have a real opportunity to accelerate the adoption of solutions that improve prevention, tackle health inequalities and deliver better outcomes for patients.”
Dr Rishi Das-Gupta, Chief Executive Officer of the Health Innovation Network South London said: “CVD is the largest avoidable causes of death and requires behaviour change to improve. We are excited about working on this programme using our long history of working with the private healthcare providers which acts as a good test environment for change programmes that can be used and rolled out across the NHS to make an impactful difference.”



